Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
2023年 9月 18日
Read MoreZai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
2023年 8月 30日
Read MoreZai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
2023年 8月 07日
Read MoreZai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
2023年 7月 20日
Read MoreJAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
2023年 7月 19日
Read MoreZai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
2023年 7月 17日
Read MoreZai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
2023年 7月 14日
Read More